Premium
A neuromuscular‐based analysis of the open payments program
Author(s) -
Harada Yohei,
Sheng Sen,
Thombre Vaishali A.,
Ounpraseuth Songthip,
Tommee Carolina Gil,
Annapureddy Amarnath R.,
Kamran Mudassar,
Jasti Madhu S.,
Katsuno Masahisa,
Yadala Sisira,
Veerapaneni Karthika,
Kapoor Nidhi,
Kovvuru Sukanthi,
Onteddu Sanjeeva Reddy,
Nalleballe Krishna
Publication year - 2021
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.27016
Subject(s) - medicaid , payment , medicine , business , finance , health care , economics , economic growth
In August 2013, the Centers for Medicare and Medicaid Services (CMS) Open Payments Program (OPP) made eligible payment information publicly available. Data about industry payments to neuromuscular neurologists are lacking. Method Financial relationships were investigated between industry and US neuromuscular neurologists from January 2014 through December 2018 using the CMS OPP database. Results The total annual payments increased more than 6‐fold during the study period. The top 10% of physician‐beneficiaries collected 80% to 90% of total industry payments except in 2014. In 2018, the most common drugs associated with payments to neuromuscular neurologists were nusinersen, vortioxetine, eteplirsen, alglucosidase alpha, edaravone, and intravenous immunoglobulin. Discussion A substantial increase in the annual payments to neuromuscular physicians during the study period is likely due to the development of new treatments, including gene therapy.